Navigation Links
Owing to Generic Erosion of Key Agents, the Colorectal Cancer Drug Market Will Remain Relatively Flat Through 2019

BURLINGTON, Mass., Sept. 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, owing to generic erosion of key agents, the colorectal cancer drug market will remain relatively flat over the next decade, increasing from more than $6.4 billion in 2009 to just under $6.7 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

The Pharmacor 2010 findings from the topic entitled Colorectal Cancer reveal that the market leader -- Genentech/Roche/Chugai's Avastin -- will be minimally challenged in the colorectal cancer drug market over the next decade. Despite the emergence of biosimilar versions of Avastin, which is expected to begin in 2018, and increasing first-line use of other targeted agents, Avastin sales will decline only slightly from just over $2 billion in 2009 to $1.86 billion in 2019. Additionally, the entry of two new vascular endothelial growth factor (VEGF)-targeted agents into the market, Regeneron/Sanofi-Aventis's aflibercept (VEGF Trap) and ImClone Systems/Eli Lilly's ramucirumab, will fail to make a significant impact, together garnering only 4.9% of major market sales.

The Pharmacor 2010 findings also reveal that Bristol-Myers Squibb/ImClone Systems/Merck Serono's Erbitux dominates the epidermal growth factor receptor (EGFR) inhibitors class, mainly because it was first drug in its class to launch for the indication, it can be used in combination with chemotherapy and has been approved in Europe and Japan for use in the lucrative first-line setting.

"Through 2019, Erbitux's market share will grow incrementally, even in the face of biogeneric erosion and the use of additional anti-EGFR treatments in the first- and second-line settings," said Decision Resources Analyst Regina Jammen. "Erbitux's first-to-market position has helped establish it as the market-leading anti-EGFR therapy."

The findings also reveal that, although a variety of suitable treatments for the indication are available, new therapies are required that will meet the needs of subsets of colorectal cancer patients. Several treatments that are expected to launch by 2019 will meet some of the needs of heavily pretreated patients with KRAS (Kirsten rat sarcoma viral oncogene homologue) mutations, patients with liver metastases and high-risk stage II patients. These late-stage therapies include AEterna Zentaris/Keryx Biopharmaceuticals' perifosine (KRX-0401), Light Sciences Oncology/Nippon Petrochemicals/Meiji Seika Kaisha's Aptocine/Laserphyrin (talaporfin) and the OncoVax vaccine, Vaccinogen.

"However, we forecast that none of these late-stage therapies will achieve blockbuster sales for colorectal cancer," Ms. Jammen said.

About Pharmacor 2010The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision ResourcesDecision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision Resources, Inc.Christopher Comfort781-993-2597

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
2. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
3. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
4. Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery
5. Anesiva Initiates Phase 2 Trial with Adlea(TM) for Pain Relief Following Total Hip Replacement Surgery
6. Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
7. Human Genome Sciences Presents New Data Showing Anti-Tumor Activity And Safety Of Trail Receptor Antibodies In Combination With Chemotherapy
8. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
9. IDM Pharma Announces Updated Phase 2 UVIDEM(R) Results Showing Durable Disease Control and Tolerability in Advanced Melanoma Patients
10. VIA Pharmaceuticals Presents Data at American Heart Association Meeting Showing VIA-2291 Significantly Reduces Inflammation in Preclinical Model of Atherosclerosis
11. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
Post Your Comments:
(Date:12/1/2015)... Virginia , 1 de diciembre de ... en tecnología para cuchillas de precisión, develó ... programa de identidad de marca. El nuevo ... el diseño y la ingeniería de productos ... la diferencia". ...
(Date:12/1/2015)... 1, 2015 Breg, Inc ., a ... today that it has been awarded three contracts by ... by Novation will have access to improved pricing for ... and soft goods dedicated to advancing orthopedic care.  ... aging U.S. population, rising prevalence of chronic conditions and ...
(Date:12/1/2015)... India , December 1, 2015 ... a new market research report "Nucleic Acid Labeling Market ... (PCR, Nick Translation, Random Primer, In Vitro Transcription, Reverse ... 2020", published by MarketsandMarkets, The global market is expected ... 1,271.8 Million in 2015, growing at a CAGR of ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... Royal River Natural Foods ... study that found post-menopausal women who took the nutritional supplement creatine, along with resistance ... trained but did not take creatine. , The report is part of the December ...
(Date:12/1/2015)... ... ... Integrated Rental Services (“Integrated Rental”), a growing medical equipment ... With support from JII, Integrated Rental is poised for expansion while improving its ... labs and medical facilities across the United States. , General Manager Robert Bean ...
(Date:12/1/2015)... , ... December 01, 2015 , ... Florida Hospital Tampa is the first ... obesity in the state of Florida. , vBloc® Therapy is a vagal blocking therapy, delivered ... years with a body mass index (BMI) of at least 40 to 45 kg, or ...
(Date:12/1/2015)... Los Angeles, CA (PRWEB) , ... December 01, 2015 , ... ... a coalition of obesity groups has filed a discrimination claim against the U.S. Department ... surgery coverage in their Affordable Care Act (ACA) plans are breaking the clause in ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... oncology and hematology continuing medical education (CME), today announced that the first annual ... Hyatt New York. , “The prevention, detection and treatment of gastrointestinal cancers are ...
Breaking Medicine News(10 mins):